- PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations
[作者：Janku, F; Wheler, JJ; Westin, SN; Moulder, SL; Naing, A; Tsimberidou, AM; Fu, SQ; Falchook, GS; Hong, DS; Garrido-Laguna, I; Luthra, R; Lee, JJ; Lu, KH; Kurzrock, R,期刊：Journal of clinical oncology, 页码：777-782 , 文章类型： Article，,卷期：2012年30-8]
- Purpose Mutations of the PIK3CA gene may predict response to phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) inhibitors. Concomitant mutations in the mitogen-activated protein kinase (MAPK) ...
- Uptake and Economic Impact of First-Cycle Colony-Stimulating Factor Use During Adjuvant Treatment of Breast Cancer
[作者：Hershman, DL; Wilde, ET; Wright, JD; Buono, DL; Kalinsky, K; Malin, JL; Neugut, AI,期刊：Journal of clinical oncology, 页码：806-812 , 文章类型： Article，,卷期：2012年30-8]
- Purpose In 2002, pegfilgrastim was approved by the US Food and Drug Administration and the benefits of dose-dense breast cancer chemotherapy, especially for hormone receptor (HR)-negative tumors, were reported. We examin...
- Prospective Study of Factors Predicting Adherence to Surveillance Mammography in Women Treated for Breast Cancer
[作者：Shelby, RA; Scipio, CD; Somers, TJ; Soo, MS; Weinfurt, KP; Keefe, FJ,期刊：Journal of clinical oncology, 页码：813-819 , 文章类型： Article，,卷期：2012年30-8]
- Purpose This prospective study examined the factors that predicted sustained adherence to surveillance mammography in women treated for breast cancer. Methods Breast cancer survivors (N = 204) who were undergoing surveil...
- Randomized Phase III Study Comparing Paclitaxel-Bleomycin, Etoposide, and Cisplatin (BEP) to Standard BEP in Intermediate-Prognosis Germ-Cell Cancer: Intergroup Study EORTC 30983
[作者：de Wit, R; Skoneczna, I; Daugaard, G; De Santis, M; Garin, A; Aass, N; Witjes, AJ; Albers, P; White, JD; Germa-Lluch, JR; Marreaud, S; Collette, L,期刊：Journal of clinical oncology, 页码：792-799 , 文章类型： Article，,卷期：2012年30-8]
- Purpose To compare the efficacy of four cycles of paclitaxel-bleomycin, etoposide, and cisplatin (T-BEP) to four cycles of bleomycin, etoposide, and cisplatin (BEP) in previously untreated patients with intermediate-prog...
- ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
[作者：Bergethon, K; Shaw, AT; Ou, SHI; Katayama, R; Lovly, CM; McDonald, NT; Massion, PP; Siwak-Tapp, C; Gonzalez, A; Fang, R; Mark, EJ; Batten, JM; Chen, HQ; Wilner, KD; Kwak, EL; Clark, JW; Carbone, DP; Ji, HB; Engelman, JA; Mino-Kenudson, M; Pao, W; Iafrate, AJ,期刊：Journal of clinical oncology, 页码：863-870 , 文章类型： Article，,卷期：2012年30-8]
- Purpose Chromosomal rearrangements involving the ROS1 receptor tyrosine kinase gene have recently been described in a subset of non-small-cell lung cancers (NSCLCs). Because little is known about these tumors, we examine...
- Sequential Versus Single High-Dose Chemotherapy in Patients With Relapsed or Refractory Germ Cell Tumors: Long-Term Results of a Prospective Randomized Trial
[作者：Lorch, A; Kleinhans, A; Kramar, A; Kollmannsberger, CK; Hartmann, JT; Bokemeyer, C; Rick, O; Beyer, J,期刊：Journal of clinical oncology, 页码：800-805 , 文章类型： Article，,卷期：2012年30-8]
- Purpose To evaluate the long-term survival rates in patients with relapsed or refractory germ cell tumors (GCTs) after single or sequential high-dose chemotherapy (HDCT). Patients and Methods Between November 1999 and No...
- Short, Full-Dose Adjuvant Chemotherapy in High-Risk Adult Soft Tissue Sarcomas: A Randomized Clinical Trial From the Italian Sarcoma Group and the Spanish Sarcoma Group
[作者：Gronchi, A; Frustaci, S; Mercuri, M; Martin, J; Lopez-Pousa, A; Verderio, P; Mariani, L; Valagussa, P; Miceli, R; Stacchiotti, S; Dei Tos, AP; De Paoli, A; Longhi, A; Poveda, A; Quagliuolo, V; Comandone, A; Casali, PG; Picci, P,期刊：Journal of clinical oncology, 页码：850-856 , 文章类型： Article，,卷期：2012年30-8]
- Purpose A previous randomized clinical trial by the Italian Sarcoma Group (ISG) had shown a survival benefit of adjuvant chemotherapy (CT) in high-risk extremity soft tissue sarcoma (STS). However, the dose-intensity of ...
|